At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 162 enrolled
Drug / intervention
Zilucoplan +1 moredrug
Likely dose
Zilucoplan 0.3mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HEALEY ALS Platform Trial - Regimen A Zilucoplan
In Brief
A Phase 3 clinical trial evaluating Zilucoplan and Matching Placebo for Amyotrophic Lateral Sclerosis. Completed, enrolled 162 participants across 1 site.
Detailed Summary
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen A will evaluate the safety and efficacy of a single study drug, zilucoplan, in participants with ALS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesUnited States
CollaboratorsRa Pharmaceuticals
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionApr 2022
Study CompletionMay 2022
TodayJul 2026
First PostedJun 18, 2020
Enrollment StartJul 29, 2020
Primary CompletionApr 13, 2022
Study CompletionMay 4, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.0 years ago
Interventions
Zilucoplandrug
Drug: Zilucoplan Administration: Subcutaneous injection Dosage: 0.3mg/kg administered daily
Matching Placebodrug
Drug: Matching Placebo Administration: Subcutaneous injection Dosage: Daily subcutaneous injection